NeuroOne Medical Technologies Expected to Join Russell Microcap Index
Medical technology company NeuroOne Medical Technologies (NASDAQ: NMTC) has announced its expected inclusion in the Russell Microcap Index as part of the index's semi-annual reconstitution.
NeuroOne Medical Technologies Notified of Preliminary Inclusion in Russell Microcap Index
Date: June 16, 2026
Eden Prairie, Minnesota – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, announced it is expected to join the Russell Microcap Index. The inclusion is part of the 2026 semi-annual Russell indexes reconstitution, which takes effect after market close on Friday, June 26, 2026.
The company, which develops and markets FDA-cleared electrode and ablation technologies, views this expected index inclusion as a reflection of its commercial progress and growing recognition within the investment community.
"We are pleased that NeuroOne is expected to be added to the Russell Microcap Index," stated CEO Dave Rosa. "We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community."
Rosa added that membership in the index is expected to increase the company's visibility among institutional investors and broaden its shareholder base as it continues its mission to transform the treatment of neurological disorders. FTSE Russell has transitioned its U.S. Indexes reconstitution schedule to a semi-annual process starting in 2026.